Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00723086 |
The purpose of this study is to evaluate the safety of docetaxel administered every 3 weeks repeatedly for 11 and more cycles and in combination with daily prednisolone for metastatic hormone refractory prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Therapy, Prostatic Neoplasms |
Drug: docetaxel (XRP6976) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Extension Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer. |
Estimated Enrollment: | 42 |
Study Start Date: | May 2005 |
Study Completion Date: | September 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients who completed the 10 cycles of docetaxel administrations in the preceding XRP6976J/2101 study and wish to continue docetaxel administrations,and who have no alternative therapy for hormone refractory prostate cancer according to the Investigator's judgment.
Exclusion Criteria:
Responsible Party: | sanofi-aventis ( ICD Study Director ) |
Study ID Numbers: | ARD6563, XRP6976J/2102 |
Study First Received: | July 24, 2008 |
Last Updated: | October 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00723086 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
docetaxel, prednisolone, drug combination |
Anti-Inflammatory Agents Antineoplastic Agents, Hormonal Genital Neoplasms, Male Prostatic Diseases Methylprednisolone Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Methylprednisolone acetate Urogenital Neoplasms |
Prednisolone acetate Genital Diseases, Male Neuroprotective Agents Glucocorticoids Hormones Docetaxel Prednisolone Peripheral Nervous System Agents Prostatic Neoplasms Methylprednisolone Hemisuccinate |
Anti-Inflammatory Agents Prostatic Diseases Genital Neoplasms, Male Methylprednisolone Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Prednisolone acetate Urogenital Neoplasms Neuroprotective Agents Hormones Docetaxel Neoplasms by Site Therapeutic Uses |
Methylprednisolone Hemisuccinate Antineoplastic Agents, Hormonal Gastrointestinal Agents Methylprednisolone acetate Genital Diseases, Male Protective Agents Glucocorticoids Pharmacologic Actions Neoplasms Autonomic Agents Prednisolone Peripheral Nervous System Agents Central Nervous System Agents Prostatic Neoplasms |